In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Disease surveillance and vaccine development
In this article in Life Science Review, Dinah Knotts, Vice President, project management, Vaccines and Infectious Disease, ICON plc outlines how disease surveillance can play an important role in emerging infectious disease early.
-
Realising the benefits of bringing the trial to the patient
In this article in Clinical Research News, Ashmee Bharadia, Vice President for Accellacare in Home Services, outlines how in-home services are being baked into trials because of their value in supporting patient-centric trials with decentralised components.
-
The most explored endpoints in decentralised clinical trials
Harpreet Gill, Vice President of Decentralised Clinical Trials and Keith Thomas, Senior Director, Digital Health Technologies contribute to this article in Clinical Trials Arena that investigates decentralisation from the perspective of trial endpoints or outcome measures.
-
Transfer of marketing authorisation
In this interview with BioPharma Reporter, Alma Salibasic, Regulatory Affairs Manager, discusses the role of a Marketing Authorisation Transfer during mergers and acquisitions in the bio pharma industry.
-
Challenges of expanding CAR-T Cell Therapy into solid tumors
Learn more about the challenges associated with developing CAR-T therapies for solid tumors in this article.
© Huber, B.; Joeckel, T. Challenges of Expanding CAR-T Cell Therapy into Solid Tumors. BioPharm International 2023, 36 (5), 22–23,27
-
Clinical Data Management
In this article, Michael Phillips, discusses the ways in which machine learning can replace or augment traditional data review approaches while maintaining a risk-based, patient-centric approach and delivering higher quality outcomes with less human error.
-
The human condition
In this article, Patricia Murphy discusses how the industry needs to make rare disease clinical trials more human.
-
Making accessibility strategy part of your rare disease trial planning
In this article, Laura Iliescu, director of patient advocacy strategy at ICON Plc, discusses strategies to improve inclusion of people with disabilities in rare disease trials.
-
How decentralised and hybrid clinical trials can support subject recruitment and retention to support clinical trial success
Read Laney Preheim's article in International Pharmaceutical Industry.
-
Diverse teams drive great performance
Steve Cutler participated in the Business & Finance CEO Q&A in which he outlined his ambitions and priorities for ICON.
